Showing results (91-100 of 394) with videos related to
Sort By:
Pageof 40
The Journal of Arthroplasty|March 26, 2013
Factors associated with poor outcomes following unicompartmental knee arthroplasty: redefining the "classic" indications for surgeryScott A J Thompson, Barthelemy Liabaud, Kate W Nellans, et al.Clinical and Experimental Dermatology|July 1, 1993
Degos disease and spastic paraplegiaT A Leslie, P C Goldsmith, A J Thompson, et al.Annals of Neurology|August 1, 1997
The impact of inpatient rehabilitation on progressive multiple sclerosisJ A Freeman, D W Langdon, J C Hobart, et al.The Quarterly Journal of Medicine|January 1, 1986
A clinical and laboratory study of benign multiple sclerosisA J Thompson, M Hutchinson, J Brazil, et al.Journal of Neurology, Neurosurgery, and Psychiatry|January 25, 2000
Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosisJ A Freeman, J C Hobart, D W Langdon, et al.Journal of Neurology|August 27, 1999
Problems in designing and recruiting to therapeutic trials in primary progressive multiple sclerosisS M Leary, V L Stevenson, D H Miller, et al.Biochimica Et Biophysica Acta|May 9, 2001
The Val-210-Ile pathogenic Creutzfeldt-Jakob disease mutation increases both the helical and aggregation propensities of a sequence corresponding to helix-3 of PrP(C)A J Thompson, K J Barnham, R S Norton, et al.Brain : a Journal of Neurology|August 7, 2003
Primary progressive multiple sclerosis: a 5-year clinical and MR studyG T Ingle, V L Stevenson, D H Miller, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|August 26, 2004
Magnetic resonance imaging predictors of disability in primary progressive multiple sclerosis: a 5-year studyV L Stevenson, G T Ingle, D H Miller, et al.The Journal of Pharmacology and Experimental Therapeutics|July 22, 2011
Varenicline is a potent agonist of the human 5-hydroxytryptamine3 receptorS C R Lummis, A J Thompson, M Bencherif, et al.Pageof 40